0000000000895222

AUTHOR

Francesco Patti

showing 39 related works from this author

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

2014

Objective: The objective of this paper is to identify clinical or magnetic resonance imaging (MRI) predictors of long-term clinical progression in a large cohort of multiple sclerosis (MS) patients. Methods: A total of 241 relapsing–remitting (RR) MS patients were included in a nine-year follow-up (FU) study. The reference MRIs were acquired at baseline (BL) as part of a multicenter, cross-sectional, clinical-MRI study. Volumetric MRI metrics were measured by a fully automated, operator-independent, multi-parametric segmentation method. Clinical progression was evaluated as defined by: conversion from RR to secondary progressive (SP) disease course; progression of Expanded Disability Status…

AdultMalemedicine.medical_specialtyMagnetic resonance imaging follow-up multiple sclerosis clinical predictors gray matter atrophypredictormultiple sclerosisDisease courseDisability EvaluationMultiple Sclerosis Relapsing-RemittingInternal medicinefollow-upmedicineHumansSecondary progressiveExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionFollow up studiesMagnetic resonance imagingclinical predictorsMiddle Agedmedicine.diseaseMagnetic Resonance Imaginggray matter atrophyCross-Sectional StudiesNeurologymultiple sclerosiDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessNuclear medicineClinical progressionMRIFollow-Up StudiesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability.

2007

Abstract Background Fatigue is a major problem in multiple sclerosis (MS), and its association with MRI features is debated. Objective To study the correlation between fatigue and lesion load, white matter (WM), and grey matter (GM), in MS patients independent of disability. Methods We studied 222 relapsing remitting MS patients with low disability (scores ≤ 2 at the Kurtzke Expanded Disability Status Scale). Lesion load, WM and GM were measured by fully automated, operator-independent, multi-parametric segmentation method. T1 and T2 lesion volume were also measured by a semi-automated method. Fatigue was assessed by the Fatigue Severity Scale (FSS), and patients divided in high-fatigue (FS…

AdultMalemedicine.medical_specialtyMultiple SclerosisStatistics as TopicGrey matterLesionWhite matterCentral nervous system diseaseDisability EvaluationAtrophyInternal medicinemedicineImage Processing Computer-AssistedHumansRisk factorFatigueAnalysis of VarianceBrain Mappingbusiness.industryMultiple sclerosisBrainmedicine.diseaseMagnetic Resonance ImagingSurgeryOxygenMultiple Sclerosis fatiguemedicine.anatomical_structureNeurologymultiple sclerosiFemaleNeurology (clinical)Analysis of variancemedicine.symptomAtrophybusinessbrain atrophyMRI
researchProduct

Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.

2022

Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different data-driven SPMS definitions. Methods: Data-driven SPMS definitions based on a version of Lorscheider’s algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist’s definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC). Results: A cohort of 10,240 MS patients wi…

Multiple SclerosisMultiple Sclerosis Chronic ProgressiveMultiple sclerosisMultiple Sclerosis Relapsing-RemittingNeurologybig dataArea Under Curvedata-driven algorithmdisease registrysecondary progressiveHumansSettore MED/26 - NeurologiaNeurology (clinical)prognosisMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

2022

Portaccio et al. report that in early relapsing-onset multiple sclerosis, progression independent of relapse activity is an important contributor to disability accumulation. Insidious progression occurs even in the earliest disease phases, suggesting that inflammation and degeneration may represent a single disease continuum.Disability accrual in multiple sclerosis may occur as relapse-associated worsening or progression independent of relapse activity. The role of progression independent of relapse activity in early multiple sclerosis is yet to be established. The objective of this multicentre, observational, retrospective cohort study was to investigate the contribution of relapse-associa…

Multiple Sclerosisrelapse-associated worseningprogression independent of relapse activityrelapsing multiple sclerosisCohort StudiesMultiple Sclerosis Relapsing-Remittingrelapse associated worseningRecurrenceChronic DiseaseDisease ProgressionHumansSettore MED/26 - NeurologiaNeurology (clinical)Retrospective Studies
researchProduct

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

2005

Objective: To measure white matter (WM) and gray matter (GM) atrophy and lesion load in a large population of patients with multiple sclerosis (MS) using a fully automated, operator-independent, multiparametric segmentation method. Methods: The study population consisted of 597 patients with MS and 104 control subjects. The MRI parameters were abnormal WM fraction (AWM-f), global WM-f (gWM-f), and GM fraction (GM-f). Results: Significant differences between patients with MS and control subjects included higher AWM-f and reduced gWM-f and GM-f. MRI data showed significant differences between patients with relapsing-remitting and secondary progressive forms of MS. Significant correlations bet…

AdultMalePathologymedicine.medical_specialtyAdolescentBrain mappingNerve Fibers MyelinatedCentral nervous system diseaseWhite matterMultiple sclerosisAtrophySex FactorsPredictive Value of TestsNeural PathwaysmedicineHumansAge of OnsetMultiple Sclerosis/physiopathologyAgedCross-Sectional StudieBrain MappingExpanded Disability Status Scalemedicine.diagnostic_testBrain/physiopathologybusiness.industryMultiple sclerosisBrainMagnetic resonance imagingInterferon-betaMiddle Agedmedicine.diseasePrognosislesion loadMagnetic Resonance ImagingMultiple Sclerosis/diagnosimedicine.anatomical_structureCross-Sectional Studiesmultiple sclerosiLinear ModelsDisease ProgressionEducational StatusFemaleNeurology (clinical)Age of onsetAtrophybusinessMultiple Sclerosis/complicationbrain atrophyMRI
researchProduct

Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

2021

Importance Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. Objective To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. Design, Setting, and Participants Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59 000 patients. Inclusion criteria were…

MaleRegistriePediatricsAdolescent; Adult; Age of Onset; Aged; Child; Child Preschool; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Registries; Retrospective Studies; Risk Factors; Young Adult; Disabled Persons; Disease ProgressionRisk of Disability0302 clinical medicineRisk FactorsRetrospective StudieMultiple Sclerosi030212 general & internal medicineRegistriesAge of OnsetChildOriginal InvestigationHazard ratioConfoundingMiddle Agedpediatric-onset MS (POMS)Italytherapeutic and managing standardsChild PreschoolDisease ProgressionSettore MED/26 - NeurologiaFemaleDisabled PersonHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentMEDLINEProfile of mood states03 medical and health sciencesYoung AdultmedicineHumansIn patientDisabled PersonsPreschoolpediatric-onset MS (POMS) therapeutic and managing standardsRetrospective StudiesAgedExpanded Disability Status Scalebusiness.industryPediatric-Onset Multiple SclerosisMultiple sclerosisRisk Factormedicine.diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Impact of sociodemographic characteristics on cognitive performance in an elderly Sicilian population.

2002

<i>Objective:</i> To assess cognitive levels in an elderly Sicilian population and to evaluate the role of education and other sociodemographic characteristics in cognitive performance. <i>Background:</i> The pattern of cognitive performance in the elderly has not been investigated extensively in well-defined Italian populations. This study was conducted as part of a door-to-door survey of common neurologic disorders (the Sicilian Neuro-Epidemiologic Study project). <i>Methods:</i> Thirteen physicians administered an Italian version of the Short Portable Mental Status Questionnaire (SPMSQ) to all subjects aged 50 years or older who, on November 1, 1987, r…

GerontologyMaleMental Status ScheduleMultivariate analysisPsychometricsPsychometricsCross-sectional studyEpidemiologyPopulationSociodemographic characteristicDoor-to-door surveyAlzheimer DiseaseRisk FactorsMedicineHumansEffects of sleep deprivation on cognitive performanceeducationSicilyAgedAged 80 and overeducation.field_of_studybusiness.industryCognitionMiddle Agedmedicine.diseaseCognitive impairmentCross-Sectional StudiesSocioeconomic FactorsSicilian Neuro-Epidemiologic Study projectEducational StatusSettore MED/26 - NeurologiaFemaleNeurology (clinical)Alzheimer's diseasebusinessCognition DisordersMental Status ScheduleNeuroepidemiology
researchProduct

Stroke in the young in sicily: Prevalence and clinical features

1998

Few epidemiological reports focus on the prevalence of stroke in the young population. As part of a neuroepidemiological survey on the total population of three Sicilian municipalities, we assessed the prevalence of stroke in the young, describing the clinical features of each patient. We screened 14,832 subjects younger than 40 years with a door-to-door method and a two-phase study design. Phase 1 consisted of a questionnaire and a brief neurological examination; phase 2 was an extensive evaluation performed by a neurologist. On the prevalence day (November 1, 1987), we ascertained six cases of stroke (prevalence rate, 40.5/100,000). Three were hemorrhagic, one ischemic, and two of uncerta…

Pediatricsmedicine.medical_specialtymedicine.diagnostic_testbusiness.industryEpidemiologyRehabilitationPrevalenceYoungNeurological examinationTotal populationmedicine.diseaseStrokeAcquired immunodeficiency syndrome (AIDS)Young populationEpidemiologymedicinePrevalenceMotor recoverySurgerySettore MED/26 - NeurologiaNeurology (clinical)businessCardiology and Cardiovascular MedicineStroke
researchProduct

Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia

2010

Mutations in the SPG4 gene are the most common causes of hereditary spastic paraplegia (HSP) accounting for up to 40% of autosomal dominant (AD) forms and 12-18% of sporadic cases. The phenotype associated with HSP due to mutations in the SPG4 gene tends to be pure. There is increasing evidence, however, of patients with complicated forms of spastic paraplegia in which SPG4 mutations were identified. A cohort of 38 unrelated Italian patients with spastic paraplegia, of which 24 had a clear dominant inheritance and 14 were apparently sporadic, were screened for mutations in the SPG4 gene.We identified 11 different mutations, six of which were novel (p.Glu143GlyfsX8, p.Tyr415X, p.Asp548Asn, c…

MaleSpastinDNA Mutational AnalysisHereditary spastic paraplegiaEXON DELETIONSGene mutationmedicine.disease_causeSpastinFAMILIESCohort StudiesExonGenotypeSpasticMutation frequencyChild3' Untranslated RegionsChromatography High Pressure LiquidAdenosine TriphosphatasesGeneticsMutationHereditary spastic paraplegia SPG4Reverse Transcriptase Polymerase Chain ReactionMutation analysiExonsMiddle AgedMLPAPhenotypeMutation analysisItalyNeurologySettore MED/26 - NeurologiaFemaleAdultAdolescentGenotypeHereditary spastic paraplegia3 ' UTR3′ UTRMutation MissenseFREQUENTSPG4CLASSIFICATIONYoung AdultmedicineHumansAgedParaplegiaSPECTRUMbusiness.industrymedicine.diseaseNeurology (clinical)businessCOLLECTIONEXPRESSION ANALYSISGene Deletion
researchProduct

Stroke incidence and survival in three Sicilian municipalities

1998

We investigated the incidence of first-ever stroke in three Sicilian municipalities over the years 1984–1987. Case ascertainment involved two approaches: a doorto-door two-phase prevalence survey and a study of death certificates. Only first-ever strokes occurring within the study time interval were included, and diagnoses were based on specified criteria. We found 138 subjects who had experienced a first stroke over 73 488 person-years; the average incidence rate (new cases per 1000 population per year) was 1.9 overall, 1.7 in men, and 2.1 in women. Incidence increased steeply with age and was similar in men and women. Incidence was similar in the three study municipalities. The overall ca…

medicine.medical_specialtyPediatricsNeurologySurvivalEpidemiologyPopulationEpidemiologyMedicineeducationSicilyStrokeNeuroradiologyeducation.field_of_studyNeuroscience (all)business.industryIncidenceGeneral NeuroscienceIncidence (epidemiology)medicine.diseaselanguage.human_languageStrokeItalyPsychiatry and Mental HealthlanguageSettore MED/26 - NeurologiaNeurology (clinical)businessStroke incidenceSicilian2708
researchProduct

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study

2009

Background To investigate in a large cohort of patients with multiple sclerosis (MS), lesion load and atrophy evolution, and the relationship between clinical and magnetic resonance imaging (MRI) correlates of disease progression. Methods Two hundred and sixty-seven patients with MS were studied at baseline and two years later using the same MRI protocol. Abnormal white matter fraction, normal appearing white matter fraction, global white matter fraction, gray matter fraction and whole brain fraction, T2-hyperintense, and T1-hypointense lesions were measured at both time points. Results The majority of patients were clinically stable, whereas MRI-derived brain tissue fractions were signifi…

AdultMalePathologymedicine.medical_specialtyAdolescentCentral nervous systemmultiple sclerosisSeverity of Illness IndexLesion loadWhite matterCentral nervous system diseaseYoung AdultDegenerative diseaseAtrophyMultiple Sclerosis Relapsing-RemittingatrophyRisk FactorsT2 lesionsmedicinefollow upHumansAgedmedicine.diagnostic_testbusiness.industryMultiple sclerosisBrain AtrophyBrainMagnetic resonance imagingMiddle AgedMultiple Sclerosis Chronic Progressivelesion loadmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureCross-Sectional StudiesLogistic ModelsNeurologymultiple sclerosiMultivariate AnalysisDisease ProgressionFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesMRI
researchProduct

Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients

2015

Background: Magnetic Resonance Imaging (MRI) techniques provided evidences into the understanding of cognitive impairment (CIm) in Multiple Sclerosis (MS). Objectives: To investigate the role of white matter (WM) and gray matter (GM) in predicting long-term CIm in a cohort of MS patients. Methods: 303 out of 597 patients participating in a previous multicenter clinical-MRI study were enrolled (49.4% were lost at follow-up). The following MRI parameters, expressed as fraction (f) of intracranial volume, were evaluated: cerebrospinal fluid (CSF-f), WM-f, GM-f and abnormal WM (AWM-f), a measure of lesion load. Nine years later, cognitive status was assessed in 241 patients using the Symbol Dig…

EMTREE medical terms: Articlerecalllcsh:MedicineAudiologyNeuropsychological TestsNerve Fibers Myelinated030218 nuclear medicine & medical imagingCohort Studies0302 clinical medicinecognitive defectnuclear magnetic resonance imaginglcsh:ScienceModified Card Sorting TestMultidisciplinaryneuroimagingSemantically Related Word List TestMultiple Sclerosis Cognitive Dysfunction MRImedicine.diagnostic_testpredictive valueBrainCognitionNeuropsychological testgray matterMiddle AgedPrognosisMagnetic Resonance ImagingMemory Short-Termfemalebrain sizemultiple sclerosiCohortDisease ProgressionSettore MED/26 - Neurologiawhite matterResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisPaced Auditory Serial Addition Testverbal memorycerebrospinal fluidworking memory03 medical and health sciencesmalemedicineHumanscontrolled studyhumanRecallbusiness.industryMultiple sclerosislcsh:RMagnetic resonance imagingmedicine.diseasemajor clinical studyattentionexecutive functionSymbol Digit Modalities TestPaced Auditory Serial Addition Testneuropsychological testlcsh:QVerbal memorybusinessCognition Disorders030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Prevalence of Parkinson's disease and other types of parkinsonism: A door-to-door survey in three Sicilian municipalities

1992

We investigated the prevalence of Parkinson's disease and other types of parkinsonism in a Sicilian population using a door-to-door two-phase approach. This design called for the administration of a brief screening instrument to all subjects who, on November 1, 1987, were residents of Terrasini (Palermo Province), Santa Teresa di Riva (Messina Province), and Riposto (Catania Province), Sicily (N = 24,496). Study neurologists using specified diagnostic criteria extensively investigated those subjects who screened positive. We found 63 subjects affected by Parkinson's disease, 21 with secondary parkinsonism, and seven with unspecified parkinsonism. The crude prevalence per 100,000 population …

medicine.medical_specialtyeducation.field_of_studyParkinson's diseasebusiness.industryParkinsonismPopulationDiseasemedicine.diseaselanguage.human_languagenervous system diseasesDegenerative diseaseEpidemiologymedicinelanguageNeurology (clinical)businesseducationSicilianMass screeningDemographyNeurology
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.

2021

Summary Background Among asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce long-term stroke risks. However, from recent national registry data, each option causes about 1% procedural risk of disabling stroke or death. Comparison of their long-term protective effects requires large-scale randomised evidence. Methods ACST-2 is an international multicentre randomised trial of CAS versus CEA among asymptomatic patients with severe stenosis thought to require intervention, interpreted with all other relevant trials. Patients were eligib…

Malemedicine.medical_specialtyTime FactorsTime Factormedicine.medical_treatmentCarotid StenosiMEDLINECarotid endarterectomyRate ratioRisk AssessmentAsymptomaticlaw.inventionRandomized controlled triallawRisk Factorscarotid artery stenting (CAS); carotid endarterectomy (CEA)StentmedicineHumansCarotid StenosisStrokeEndarterectomyAgedEndarterectomy Carotidbusiness.industrycarotid arteryRisk FactorArticlesGeneral Medicinetrialmedicine.diseaseSettore MED/22 - CHIRURGIA VASCOLARESurgeryStrokeStenosisTreatment Outcomecarotid artery stenting (CAS)Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREFemaleStentsHuman medicinemedicine.symptomcarotid endarterectomy (CEA)businessHumanLancet (London, England)
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

Objective To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results In pCIS, female sex and a multifocal onset were risk factors for a second clinical attack (hazard ratio [HR], 95% confidence interval [CI] = 1.28, 1.06–1.55; 1.42, 1.10–1.84, respectively), whereas disease-modifying drug (DMD) exposure reduced this risk (HR, 95% CI = 0.75, 0.60–0.95…

0301 basic medicinemedicine.medical_specialtyeducation.field_of_studyClinically isolated syndromeExpanded Disability Status Scalebusiness.industryProportional hazards modelHazard ratioPopulationRetrospective cohort studySurgery03 medical and health sciences030104 developmental biology0302 clinical medicineNeurologyInternal medicineMedicineNeurology (clinical)Age of onsetRisk factorbusinesseducation030217 neurology & neurosurgeryAnnals of Neurology
researchProduct

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis

2019

: Background: The role of the neutrophil-to-lymphocyte ratio (NLR) of peripheral blood has been investigated in relation to several autoimmune diseases. Limited studies have addressed the significance of the NLR in terms of being a marker of disease activity in multiple sclerosis (MS). Methods: This is a retrospective study in relapsing&ndash

AdultMalelymphocytesmedicine.medical_specialtyAdolescentlymphocyteLogistic regressionmultiple sclerosisArticleNLR; disease activity; lymphocytes; multiple sclerosis; neutrophilsNLRCohort StudiesDisease activityLeukocyte CountYoung AdultMultiple Sclerosis Relapsing-RemittingneutrophilsInternal medicinemedicineHumansNeutrophil to lymphocyte ratiolcsh:QH301-705.5Retrospective StudiesGenetic associationbusiness.industryMultiple sclerosisfungineutrophilRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseRelapsing remittinglcsh:Biology (General)multiple sclerosiCohortDisease ProgressionFemalebusinessdisease activityBiomarkers
researchProduct

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

2009

Objective: Recent findings support greater efficacy of early vs. delayed interferon beta (IFN) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFN treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFN treatment with regard to the greatest benefits on disability progression. Methods: A cohort of 2,570 IFN-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. dela…

medicine.medical_specialtyExpanded Disability Status Scalebusiness.industryMultiple sclerosisHazard ratiomedicine.diseaseSurgeryCentral nervous system diseaseNeurologyInternal medicinePropensity score matchingCohortmedicineObservational studyNeurology (clinical)Unmeasured confoundingbusinessAnnals of Neurology
researchProduct

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020

Abstract An ever-expanding number of disease-modifying drugs for multiple sclerosis have become available in recent years, after demonstrating efficacy in clinical trials. In the real-world setting, however, disease-modifying drugs are prescribed in patient populations that differ from those included in pivotal studies, where extreme age patients are usually excluded or under-represented. In this multicentre, observational, retrospective Italian cohort study, we evaluated treatment exposure in three cohorts of patients with relapsing-remitting multiple sclerosis defined by age at onset: paediatric-onset (≤18 years), adult-onset (18–49 years) and late-onset multiple sclerosis (≥50 years). We…

AdultMalemedicine.medical_specialtyneuroinflammationCohort Studies03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansDisabled Persons030212 general & internal medicineProspective StudiesRisk factorclinical trials; clinically isolated syndrome; demyelination; multiple sclerosis epidemiology; neuroinflammationRetrospective Studiesclinical trialsClinically isolated syndromeExpanded Disability Status ScaleProportional hazards modelbusiness.industryHazard ratioMiddle AgedItalyAntirheumatic Agentsclinically isolated syndromeCohortDisease Progressionmultiple sclerosis epidemiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)demyelinationAge of onsetbusiness030217 neurology & neurosurgeryCohort studyFollow-Up Studies
researchProduct

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies

2021

Background and aims: No consensus exists on how aggressively to treat relapsing–remitting multiple sclerosis (RRMS) nor on the timing of the treatment. The objective of this study was to evaluate disability trajectories in RRMS patients treated with an early intensive treatment (EIT) or with a moderate-efficacy treatment followed by escalation to higher-efficacy disease modifying therapy (ESC). Methods: RRMS patients with ⩾5-year follow-up and ⩾3 visits after disease modifying therapy (DMT) start were selected from the Italian MS Registry. EIT group included patients who received as first DMT fingolimod, natalizumab, mitoxantrone, alemtuzumab, ocrelizumab, cladribine. ESC group patients rec…

Pediatricsmedicine.medical_specialtybig data; disability trajectories; disease registry; multiple sclerosis.multiple sclerosis03 medical and health sciences0302 clinical medicineDisease registrybig dataMedicine030212 general & internal medicineRC346-429Original Researchbig data; disability trajectories; disease registry; multiple sclerosisPharmacologybusiness.industryMultiple sclerosisLong term disabilitymedicine.diseaseNeurologydisease registryTreatment strategySettore MED/26 - Neurologiadisability trajectoriesNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Cyclophosphamide Pulse Therapy after Natalizumab Discontinuation for Multiple Sclerosis: a multicenter study.

2015

Importance: Natalizumab discontinuation induces the recurrence of Multiple Sclerosis (MS) disease activity: Currently no therapeutic approach has been found able to abolish disease reactivation. Objective: To collect data from patients with MS switching from natalizumab to cyclophosphamide. Design: Retrospective multicentre study. Setting: Nine Multiple Sclerosis Centers in Italy. Participants: A total of 47 patients with clinically definite RR-MS switched to cyclophosphamide after natalizumab discontinuation. Two patients were excluded from the analysis because received less than 12 natalizumab infusions. The remaining 45 patients were subdivided into two main groups: Early Treatment (peri…

medicine.medical_specialtyExpanded Disability Status ScaleCyclophosphamidebusiness.industryMultiple sclerosismedicine.diseaseOmicsDiscontinuationMultiple sclerosis; Natalizumab discontinuation; Disease reactivation; Cyclophosphamide; ReboundNatalizumabInternal medicineImmunologymedicineBrain magnetic resonance imagingbusinessAdverse effectmedicine.drug
researchProduct

Prevalence of stroke: A door-to-door survey in three Sicilian municipalities

1996

As part of a door-to-door survey, we screened for stroke among the inhabitants of three Sicilian municipalities (n = 24,496 as of November 1, 1987). Neurologists then investigated those subjects suspected to have had a stroke. Diagnoses of first-ever strokes were based on specified criteria and were reviewed by an adjudication panel. We found 189 subjects who had experienced at least one completed stroke (180 definite, 9 possible); 15 strokes were hemorrhagic, 71 ischemic, and 103 uncertain. The prevalence (cases/100,000) was 771.6 in the total population and 1,893.6 in those aged 40 years or over. The prevalence increased steeply with age, was higher in men between 60 and 79 years, but was…

medicine.medical_specialtyPediatricsIschemic strokebusiness.industryStroke prevalenceEpidemiologyTotal populationmedicine.diseaselanguage.human_languageEpidemiologyIschemic strokelanguageMedicineStroke epidemiologySettore MED/26 - NeurologiaSicily stroke prevalenceNeurology (clinical)businessHemorrhagic strokeStrokeCompleted strokeSicilian
researchProduct

Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.

2022

ObjectiveAssessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >−30 days and ≤90 days from conception (SHORT_EXP), and describing newborns’ outcomes.MethodsMaternal clinical and radiological outcomes and obstetric and fetal outcomes were retrospectively collected and compared among groups (NO_EXP, SHORT_EXP, LONG_EXP). Predictors of clinical and radiological reactivation were investigated through univariable and multivariable analysis.Results170 eligible pregnancies from 163 women…

Psychiatry and Mental healthSettore MED/26 - NEUROLOGIAobstetricsmultiple sclerosiobstetricSurgeryNeurology (clinical)MRI; multiple sclerosis; obstetricsSettore MED/26multiple sclerosisMRIJournal of neurology, neurosurgery, and psychiatry
researchProduct

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

Prevalence of cervical spondylotic radiculopathy: A door-to-door survey in a Sicilian municipality

1996

Introduction - Because of the limited information on cervical spondylotic radiculopathy, we conducted a door-to-door two-phase survey in a Sicilian municipality. Material and methods - We first screened for cervical spondylotic radiculopathy among the inhabitants of the municipality : (N= 7653, as of the prevalence day, November 1, 1987). Study neurologists then investigated those subjects suspected to have had a cervical spondylotic radiculopathy. Diagnoses were based on specified criteria. Results - We found 27 subjects affected by CSR (17 definite, 10 possible). Prevalence (cases per 1000 population) was 3.5 in the total population ; it increased to a peak at age 50-59 years and decrease…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyCross-sectional studyPopulationTotal populationSpinal OsteophytosisRisk FactorsEpidemiologyPrevalencemedicineHumansMass ScreeningeducationChildSicilyMass screeningAgedAged 80 and overeducation.field_of_studyNeuroscience (all)business.industryIncidence (epidemiology)IncidenceNerve Compression SyndromesInfantGeneral MedicineMiddle Agedmedicine.anatomical_structureCross-Sectional StudiesNeurologyChild PreschoolCervical spondylotic radiculopathyPhysical therapyCervical VertebraePrevalence studiesSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessSpinal Nerve RootsDemographyCervical vertebrae
researchProduct

Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

2006

This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up per…

medicine.medical_specialtyNeurologyMultiple SclerosisDermatologySeverity of Illness IndexInterferon beta • Multiple sclerosis • Phase IV • Odds ratioInternal medicineSeverity of illnessmedicineConfidence IntervalsHumansImmunologic FactorsMultiple sclerosiNeuroradiologyAnalysis of Variancemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingGeneral MedicineOdds ratioInterferon-betaOdds ratiomedicine.diseaseInterferon betaMagnetic Resonance ImagingConfidence intervalPsychiatry and Mental healthItalyPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)NeurosurgeryPhase IVbusinessFollow-Up Studies
researchProduct

Erratum to: ‘Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled tr…

2016

Protocol (science)medicine.medical_specialtybusiness.industryMultiple sclerosisMedicine (miscellaneous)medicine.diseaseHome basedlaw.invention03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationRandomized controlled triallawPhysical therapyMedicinePharmacology (medical)030212 general & internal medicineErratumbusiness030217 neurology & neurosurgeryTrials
researchProduct

Prevalence of epilepsy. A door-to-door survey in the Sicilian community of Riposto.

1996

In a door-to-door survey of common neurological disorders in Sicily (SNES Project), we administered a screening symptoms questionnaire and a brief neurological examination to detect epileptic patients. All of the subjects effectively resident in the community of Riposto on 1 November 1987 (prevalence day) were investigated (n = 9956). The subjects with a positive questionnaire or a previous diagnosis of epilepsy were extensively examined by a neurologist and then definitively classified for epilepsy by a panel of senior neurologists. The crude prevalence of active and non-active epilepsy was 3.21/1000; the prevalence of active epilepsy alone was 2.71/1000. Of the 27 active cases, sixteen we…

AdultMalemedicine.medical_specialtyPediatricsNeurologyAdolescentPrevalenceNeurological examinationEpilepsyEpidemiologymedicinePrevalenceHumansAge of OnsetChildEpilepsymedicine.diagnostic_testbusiness.industryGeneral NeuroscienceMiddle Agedmedicine.diseaseItalyPhenobarbitalFemaleNeurology (clinical)NeurosurgeryAge of onsetbusinessmedicine.drugItalian journal of neurological sciences
researchProduct

Parkinson disease survival: a population-based study

2000

Objective To evaluate whether the survival of patients with Parkinson disease (PD) is shorter than that of the general population. Design Survival was investigated in a cohort of patients with PD previously identified during a population-based prevalence study (prevalence day, November 1, 1987; reference follow-up date, October 31, 1995). The survival of patients with PD was compared with that of a control sample randomly selected from the same population (2 controls for each case, matched for age, sex, and study municipality). The causes of death in the 2 groups were also compared. Both univariate and multivariate survival analyses were performed to investigate the association with disease…

Malemedicine.medical_specialtyMultivariate analysisHeart DiseasesPopulationComorbidityCohort StudiesLevodopaAge DistributionArts and Humanities (miscellaneous)Internal medicineCause of DeathmedicinePrevalenceHumansSex DistributioneducationSurvival rateSicilySurvival analysisCause of deathAgedProportional Hazards ModelsAged 80 and overUnivariate analysiseducation.field_of_studyNeuroscience (all)Proportional hazards modelbusiness.industryParkinson DiseasePneumoniaMiddle AgedSurvival AnalysisSurgerySurvival RateMultivariate AnalysisSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessCohort study
researchProduct

An exploration of anger phenomenology in multiple sclerosis

2009

Background and purpose:  Multiple sclerosis (MS) patients are often emotionally disturbed. We investigated anger in these patients in relation to demographic, clinical, and mood characteristics. Patients and methods:  About 195 cognitively unimpaired MS patients (150 relapsing–remitting and 45 progressive) were evaluated with the State Trait Anger Expression Inventory, the Chicago Multiscale Depression Inventory, and the State Trait Anxiety Inventory. The patients’ anger score distribution was compared with that of the normal Italian population. Correlation coefficients among scale scores were calculated and mean anger scores were compared across different groups of patients by analysis of …

business.industryMultiple sclerosismedia_common.quotation_subjectAngermedicine.diseasebehavioral disciplines and activitiesCorrelationMoodNeurologymental disordersbehavior and behavior mechanismsmedicineAnxietyNeurology (clinical)Analysis of variancemedicine.symptomPrefrontal cortexbusinesspsychological phenomena and processesState-Trait Anxiety InventoryClinical psychologymedia_commonEuropean Journal of Neurology
researchProduct

Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

2020

The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed the therapeutic landscape and algorithms of RRMS treatment (1). In Europe, dimethyl fumarate (DMF) and teriflunomide (TRF) are approved as first-line agents and are often used as the initial therapeutic choice (2, 3). Pivotal trials showed the efficacy of both DMTs on controlling clinical relapses, disability accrual and magnetic resonance imaging (MRI) activity (4-8). Both DMTs had overall good tolerability. There have been no head-to-head randomized trials to compare these two DMTs; however, several real-world evidence (RWE) studies have compared DMF and TRF and provided u…

Cox models relapsing-remitting mul tiple sclerosis dimethyl fumarate teriflunomide
researchProduct

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

2023

Background and ObjectivesUncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). In this study, we compared the effect of AHSCT with that of other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active SPMS.MethodsWe collected data from the Italian Bone Marrow Transplantation Study Group and the Italian Multiple Sclerosis Register. Patients were considered eligible if treatment had been started after the diagnosis of SPMS. Disability worsening was assessed by the cumulative proportion of patients with a 6-month confirmed dis…

Hematopoietic Stem Cell TransplantationActive Secondary Progressive Multiple SclerosisNeurology (clinical)Research Article
researchProduct

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related d…

2022

Abstract Background Multiple sclerosis (MS) is characterized by phenotypical heterogeneity, partly resulting from demographic and environmental risk factors. Socio-economic factors and the characteristics of local MS facilities might also play a part. Methods This study included patients with a confirmed MS diagnosis enrolled in the Italian MS and Related Disorders Register in 2000–2021. Patients at first visit were classified as having a clinically isolated syndrome (CIS), relapsing–remitting (RR), primary progressive (PP), progressive-relapsing (PR), or secondary progressive MS (SP). Demographic and clinical characteristics were analyzed, with centers’ characteristics, geographic macro-ar…

Multiple SclerosisCenters’ characteristics; Italian Multiple Sclerosis Register; Multiple sclerosis phenotypes; Real-world dataSettore MED/42 - Igiene Generale e ApplicataItalian Multiple Sclerosis RegisterDermatologyGeneral MedicineMultiple Sclerosis Chronic ProgressiveSettore MED/26Settore SECS-S/04 - DemografiaCenters’ characteristicsMultiple sclerosis phenotypeReal-world dataSettore MED/01 - Statistica MedicaPsychiatry and Mental healthMultiple Sclerosis Relapsing-RemittingPhenotypeRecurrenceHumansFemaleSettore MED/26 - NeurologiaNeurology (clinical)Centers’ characteristicReferral and ConsultationMultiple sclerosis phenotypes
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical att…

RegistrieMaleMultiple SclerosisAdolescentAdolescent; Age of Onset; Child; Demyelinating Diseases; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis; Prognosis; Retrospective Studies; Risk Factors; Disease Progression; Registries; Neurology; Neurology (clinical)PrognosiONSET MULTIPLE-SCLEROSISCHILDHOODCHILDRENPARACLINICAL FEATURESDISABILITY PROGRESSIONNOFollow-Up StudieRisk FactorsRetrospective Studieprognostic indicatorsMultiple Sclerosipediatric multiple sclerosis prognosis indicatorsHumansRegistriesAge of OnsetChildOPTIC NEURITISRetrospective StudiesRisk FactorDemyelinating DiseaseNATURAL-HISTORYPrognosismultiple sclerosis clinically isolated syndrome prognostic indicatorsNeurologyTRANSVERSE MYELITISclinically isolated syndromeINTERFERON BETA-1BDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)FOLLOW-UPDemyelinating DiseasesFollow-Up StudiesHuman
researchProduct

Door-to-door prevalence survey of epilepsy in three Sicilian municipalities

2001

A door-to-door prevalence survey of epilepsy was conducted in 3 Sicilian municipalities, as of November 1, 1987. In phase 1, the screening by questionnaire of 24,496 eligible subjects (participation = 92%) identified 544 suspected to have epilepsy. In phase 2, neurological evaluation of the 544 subjects yielded 111 with epilepsy. Of the 111 subjects, 103 (93%) had been previously diagnosed, 68 (61%) were taking antiepileptic medication, and 81 (73%) had active epilepsy. Referring to the 81 subjects with active epilepsy, the seizure type was generalized in 60 (74%), partial in 19 (23%) and undetermined in 2 (3%). The prevalence of active epilepsy (per 1,000 population) was 3.3 overall, 3.5 f…

AdultMalePediatricsmedicine.medical_specialtyAdolescentEpidemiologyPopulationEpilepsySeizuresPrevalenceMedicineHumanseducationSurveyChildSicilyAgedAged 80 and overeducation.field_of_studyEpilepsybusiness.industryAge FactorsPrevalence surveyMiddle Agedmedicine.diseaseHealth Surveyslanguage.human_languageChild PreschoollanguageScreeningSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessSicilian
researchProduct

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

2020

IntroductionNatalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methodsThis retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the ‘Italian MS Register’. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions…

Adultmedicine.medical_specialtyPopulationmultiple sclerosisDrug Administration Schedule03 medical and health sciencesMultiple Sclerosis Relapsing-Remittingnatalizumab0302 clinical medicineNatalizumabDosing schedulesInternal medicinemedicineHumansImmunologic Factorsnatalizumab risk stratification multiple sclerosis safety effectivenessDosingeducationProportional Hazards ModelsRetrospective Studies030304 developmental biology0303 health scienceseducation.field_of_studyProportional hazards modelbusiness.industryMultiple sclerosisRetrospective cohort studyMiddle Agedmedicine.diseasePsychiatry and Mental healthTreatment OutcomeItalyTolerabilitySettore MED/26 - NeurologiaSurgeryNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

GREY MATTER ATROPHY AND FATIGUE IN MULTIPLE SCLEROSIS: A CORRELATION EVIDENT ONLY IN PATIENTS WITH LOW DISABILITY

2006

researchProduct